(Boc-Cys-OBu^t)2 | 98303-76-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (Boc-Cys-OBu^t)2
• 英文别名: (2R,2'R)-di-tert-butyl 3,3'-disulfanediylbis(2-((tert-butoxycarbonyl)amino)propanoate)；tert-butyl (2R)-3-[[(2R)-3-tert-butoxy-2-(tert-butoxycarbonylamino)-3-oxo-propyl]disulfanyl]-2-(tert-butoxycarbonylamino)propanoate；Boc-Cys(1)-OtBu.Boc-Cys(1)-OtBu；tert-butyl (2R)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-[[(2R)-3-[(2-methylpropan-2-yl)oxy]-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-oxopropyl]disulfanyl]propanoate
• CAS: 98303-76-5
• 化学式: C₂₄H₄₄N₂O₈S₂
• 分子量: 552.754
• InChiKey: GFLAHIMSYRDLRJ-HOTGVXAUSA-N

物化性质

• 沸点：
  626.8±55.0 °C(Predicted)
• 密度：
  1.139±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  36
• 可旋转键数：
  17
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  180
• 氢给体数：
  2
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  (Boc-Cys-OBu^t)2 在 三丁基膦 、 水 、 potassium hydroxide 作用下， 以 四氢呋喃 、 乙醇 、 水 为溶剂， 反应 2.0h， 生成 tert-butyl N-(tert-butoxycarbonyl)-S-((2-(8-((tert-butyldimethylsilyl)oxy)octahydroquinolin-1(2H)-yl)acetamido)methyl)-L-cysteinate
  参考文献：
  名称：

  Hydrazine-Sensitive Thiol Protecting Group for Peptide and Protein Chemistry

  摘要：

  In the search for a new Cys side-chain protecting group that is compatible to the solid-phase peptide synthesis yet can be removed under mild conditions, the Hqm and Hgm groups that are readily deprotected by using aqueous hydrazine have been developed. The utility of these groups for peptide and protein chemistry is tested by the total synthesis of a peptide antibiotic trifolitoxin and the human neutrophil defensin hNP2.

  DOI：

  10.1021/ol1028755
• 作为产物：
  描述：

  L-胱氨酸 在 4-二甲氨基吡啶 、 sodium carbonate 、 N,N'-二环己基碳二亚胺 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 水 为溶剂， 生成 (Boc-Cys-OBu^t)2
  参考文献：
  名称：

  Hydrazine-Sensitive Thiol Protecting Group for Peptide and Protein Chemistry

  摘要：

  In the search for a new Cys side-chain protecting group that is compatible to the solid-phase peptide synthesis yet can be removed under mild conditions, the Hqm and Hgm groups that are readily deprotected by using aqueous hydrazine have been developed. The utility of these groups for peptide and protein chemistry is tested by the total synthesis of a peptide antibiotic trifolitoxin and the human neutrophil defensin hNP2.

  DOI：

  10.1021/ol1028755

文献信息

• PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS
  申请人：CHEMOCENTRYX, INC.

  公开号：US20190300526A1

  公开（公告）日：2019-10-03

  The present disclosure provides, inter alia, Compounds of Formulae IA, IB, IC, IIA, IIB and IIC or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.

  本公开提供了化合物IA、IB、IC、IIA、IIB和IIC的结构，或其在药学上可接受的盐，这些化合物是C5a受体的调节剂。还提供了包括治疗涉及C5a病理性激活的疾病或疾病的药物组合物和使用方法，以及非药物应用。
• TRIAZOLE ANTIMICROBIAL DERIVATIVE, PHARMACEUTICAL COMPOSITION AND USE THEREOF
  申请人：WUHAN LL SCIENCE AND TECHNOLOG DEVELOPMENT CO.,LTD.

  公开号：US20190382375A1

  公开（公告）日：2019-12-19

  The present disclosure provides a triazole antibacterial derivative and a pharmaceutical composition thereof and a use thereof and in particular relates to a compound represented by the following formula (I), and a racemate, a stereoisomer, a tautomer, an oxynitride or a pharmaceutically acceptable salt thereof: The compound of the present disclosure has a desirable water solubility and can be formulated into an injection for use without adding a cosolvent having a potential safety risk (such as hydroxypropyl-β-cyclodextrin, sulfobutylether-β-cyclodextrin, and the like), facilitating drug administration for patients, and greatly improving clinical safety. The drug can be used even by patients with moderate or severe renal impairment, thereby expanding the application scope of the drug.

  本公开提供了一种三唑类抗菌衍生物及其药物组合物和使用方法，特别涉及以下式(I)所代表的化合物，以及其外消旋体、立体异构体、互变异构体、氧氮化物或药学上可接受的盐： 本公开的化合物具有良好的水溶性，可以制成注射剂，无需添加潜在安全风险的共溶剂（如羟丙基-β-环糊精、磺丁基醚-β-环糊精等），有助于患者用药，极大地提高了临床安全性。该药物甚至可以供中度或重度肾功能损害的患者使用，从而扩大了药物的应用范围。
• BIS(FLUOROALKYL)-1,4-BENZODIAZEPINONE COMPOUNDS AND PRODRUGS THEREOF
  申请人：Bristol-Myers Squibb Company

  公开号：US20140087992A1

  公开（公告）日：2014-03-27

  Disclosed are compounds of Formula (I) and/or salts thereof: wherein R 1 is —CH 2 CH 2 CF 3 ; R 2 is —CH 2 CH 2 CF 3 or —CH 2 CH 2 CH 2 CF 3 ; R 3 is H, —CH 3 , or R x ; R 4 is H or R y ; Ring A is phenyl or pyridinyl; and R x , R y , R a , R b , y, and z are defined herein. Also disclosed are methods of using such compounds to inhibit the Notch receptor, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as cancer; or as prodrugs of such compounds.

  公开了公式(I)的化合物及/或其盐：其中R1为-CH2CH2CF3；R2为-CH2CH2CF3或-CH2CH2CH2CF3；R3为H，-CH3或Rx；R4为H或Ry；环A为苯基或吡啶基；Rx，Ry，Ra，Rb，y和z在此定义。还公开了使用这些化合物抑制Notch受体的方法，以及包含这些化合物的药物组合物。这些化合物在治疗、预防或减缓多种治疗领域，如癌症的疾病或病症进展方面非常有用，或者作为这些化合物的前药。
• Posaconazole derivative, pharmaceutical composition and use thereof
  申请人：WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD.

  公开号：US10517867B2

  公开（公告）日：2019-12-31

  The present disclosure provides a posaconazole derivative, a pharmaceutical composition and use thereof, which specifically include a compound represented by the following formula (I), a racemate, stereoisomer, tautomer, oxynitride, or a pharmaceutically acceptable salt thereof: The compounds of the present disclosure have strong antifungal activity, high safety, and good water solubility, without the need for the addition of a cosolvent (such as hydroxypropyl-β-cyclodextrin, sulfobutyl ether-β-cyclodextrin, and the like) with potential safety risks. Furthermore, the formulation process of the compound could have less difficulty and less cost, and therefore can be used to prepare improved antifungal drugs.

  本公开提供一种泊沙康唑衍生物、药物组合物及其用途，具体包括下式（I）所代表的化合物，其外消旋体、立体异构体、互变异构体、氧氮化物或其药学上可接受的盐： 本公开的化合物具有强大的抗真菌活性、高安全性和良好的水溶性，无需添加共溶剂（如羟丙基-β-环糊精、磺基丁醚-β-环糊精等），避免潜在的安全风险。此外，该化合物的配方过程可能更加简单且成本更低，因此可用于制备改良的抗真菌药物。
• Structure-Guided Development of Potent Benzoylurea Inhibitors of BCL-X_L and BCL-2
  作者：Michael J. Roy、Amelia Vom、Toru Okamoto、Brian J. Smith、Richard W. Birkinshaw、Hong Yang、Houda Abdo、Christine. A. White、David Segal、David C. S. Huang、Jonathan B. Baell、Peter M. Colman、Peter E. Czabotar、Guillaume Lessene

  DOI：10.1021/acs.jmedchem.0c01771

  日期：2021.5.13

  Here, we outline the crystallography-guided development of a structurally distinct series of BCL-XL/BCL-2 inhibitors based on a benzoylurea scaffold, originally proposed as α-helix mimetics. We describe structure-guided exploration of a cryptic “p5” pocket identified in BCL-XL. This work yields novel inhibitors with submicromolar binding, with marked selectivity toward BCL-XL. Extension into the hydrophobic

  的BCL-2家族蛋白（包括促存活蛋白BCL-2，BCL-X大号和MCL-1）是用于新型抗癌治疗剂的发展的一个重要目标。尽管靶向小分子蛋白质相互作用的挑战，但许多抑制剂（称为BH3模拟物）已进入临床，并且BCL-2抑制剂ABT-199 / venetoclax已经证明具有转化性。对于BCL-X大号，新的验证化工系列是可取的。在这里，我们勾勒出一个结构不同的系列BCL-X的结晶学引导发展大号基于一个苯甲酰脲支架/ BCL-2抑制剂，最初提出如α螺旋模拟物。我们描述了在BCL-X L中识别出的隐秘“ p5”口袋的结构指导探索。这项工作产生了具有亚微摩尔的结合，与朝向BCL-X标记选择性新型抑制剂大号。延伸到疏水P2口袋产生最有效的抑制剂在系列，强烈结合BCL-X大号和BCL-2（纳摩尔范围的半最大抑制浓度（IC 50在工程改造到细胞）），并显示基于机制的杀伤依靠BCL-X L生存。